Pso Many New Developments:
When a market booms from multiple drug approvals for a specific disease state, so does the need to educate physicians. For a debilitating condition such as psoriasis, expanded treatment options means dermatologists can provide better patient care, and physician education is vital to ensuring these new drugs are used correctly.

In the last few years dermatologists have seen tremendous growth in the therapies available for psoriasis patients, including new biologics as well as other agents with novel formulations.

  • In 2013 the US Food and Drug Administration (FDA) approved the biologic ustekinumab (Stelara) for psoriatic arthritis, which targets IL-12 and IL-23.
  • In 2014 apremilast (Otezla), an oral medication, was approved for psoriatic arthritis first and then for plaque psoriasis later that year.
  • In 2015 we saw the approval of secukinumab (Cosentyx), an IL-17A antagonist for plaque psoriasis, and calcipotriene–betamethasone dipropionate (Enstilar), an aerosol foam, for psoriasis.
  • In March 2016 the FDA approved ixekizumab (Taltz), another IL-17A medication, for plaque psoriasis.
  • Earlier this month the FDA approved a biosimilar to infliximab (Inflectra) for plaque psoriasis and psoriatic arthritis. (A biosimilar agent is highly similar to an already-approved biologic, known as the reference product.)

Cutis, a monthly journal with a 51-year history of providing dermatologists with practical content they trust, publishes resources to keep dermatologists up-to-date on the research, the case presentations, and the issues that concern them, all housed online on our psoriasis specialty focus page. It is a one-stop shop for the dermatologist’s education needs. Referenced in Index Medicus/MEDLINE, Cutis publishes original research, case reports, and review articles on new therapies. Online we offer audio/video commentaries from key opinion leaders; blog entries on issues that concern dermatologists such as the cost of drug therapy, depression in psoriasis patients, and comorbidities; and fact sheets with critical information such as the dosing regimen and side effects of biologics. Last year we launched a psoriasis audiocast series created in collaboration with the National Psoriasis Foundation, focusing on topics such as screening for psoriatic arthritis, treating the pediatric population with psoriasis, maintaining adherence to treatments, and more.

We remain committed to being a leading resource for dermatologists. Over the last year these top-accessed articles have achieved our goal to educate dermatologists on psoriasis:

  • New Systemic Therapies for Psoriasis
  • Novel Psoriasis Therapies and Patient Outcomes, Parts 1–3
  • Depression and Psoriasis
  • Update on Pediatric Psoriasis
  • Treating Psoriasis in Pregnant Women

Questions about digital advertising opportunities, custom programs, and exclusive sponsorships in Cutis? Contact Sharon Finch, Senior Vice President/Group Publisher, at [email protected].

Melissa Sears,
Group Editor, Cutis